Gero, a Palo Alto, CA-based biotechnology company focused on aging and chronic diseases, closed $6M in a Series A extension round.
The round was led by Melnichek Investments, with participation from VitaDAO and Leonid Lozner.
The company intends to use the funds to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence.
Led by Peter Fedichev, co-founder and CEO, and co-founder Maxim Kholin, Gero is a biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself. In addition to an ongoing partnership with Pfizer to find treatments for fibrotic diseases, Gero is pursuing a longer-term plan to double human health- and lifespan within the current generation.
FinSMEs
18/10/2023